tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
ADC Therapeutics Reports Promising LOTIS-7 Trial Results
PremiumCompany AnnouncementsADC Therapeutics Reports Promising LOTIS-7 Trial Results
2M ago
Promising LOTIS-7 Trial Results Reinforce Buy Rating for ADC Therapeutics
Premium
Ratings
Promising LOTIS-7 Trial Results Reinforce Buy Rating for ADC Therapeutics
2M ago
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma
Premium
The Fly
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma
2M ago
ADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)
PremiumThe FlyADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)
3M ago
Is ADCT a Buy, Before Earnings?
Premium
Pre-Earnings
Is ADCT a Buy, Before Earnings?
3M ago
ADC Therapeutics’ LOTIS-7 Study: A Promising Update for Investors
Premium
Company Announcements
ADC Therapeutics’ LOTIS-7 Study: A Promising Update for Investors
3M ago
ADC Therapeutics announces $60M private placement
PremiumThe FlyADC Therapeutics announces $60M private placement
4M ago
Positive Buy Rating for ADC Therapeutics Amid Promising Clinical Trials and Strong Valuation
Premium
Ratings
Positive Buy Rating for ADC Therapeutics Amid Promising Clinical Trials and Strong Valuation
4M ago
ADC Therapeutics Updates Strategic Focus on ZYNLONTA
Premium
Company Announcements
ADC Therapeutics Updates Strategic Focus on ZYNLONTA
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100